Navigation Links
Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Date:2/12/2008

le by going to the Investor Relations section of the Schering-Plough corporate Web site, http://www.schering-plough.com, and clicking on the "Presentations/Webcasts" link. A replay of the webcast will be available starting on Feb. 12 through 5 p.m. on March 11.

DISCLOSURE NOTICE: The information in this press release, the comments of Schering-Plough officers during the earnings teleconference/webcast on Feb. 12, 2008, beginning at 8 a.m. (EST), and other written reports and oral statements made from time to time by the company may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements do not relate strictly to historical or current facts and are based on current expectations or forecasts of future events. You can identify these forward-looking statements by their use of words such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "project," "intend," "plan," "potential," "will," and other similar words and terms. In particular, forward-looking statements include statements relating to the company's plans; its strategies; its progress under the Action Agenda and anticipated timing regarding future performance of the Action Agenda; business prospects; anticipated growth; timing and conditions of regulatory approvals and expected synergies related to the Organon BioSciences acquisition; prospective products or product approvals; trends in performance; anticipated timing of clinical trials and its impact on R&D spending; anticipated exclusivity periods; actions to enhance clinical, R&D, manufacturing and post-marketing systems; and the potential of certain products including VYTORIN and ZETIA and trending in the cholesterol market. Actual results may vary materially from the company's forward-looking statements, and there are no guarantees about the performance of Schering- Plough stock or Schering-Pl
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
2. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
5. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
6. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
9. Schering-Plough Completes Acquisition of Organon BioSciences
10. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
11. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014 Research and Markets ... Biology Market 2014-2018" report to their offering. ... term synthetic biology covers the designing and engineering of ... as the redesigning of natural biological systems that provide ... a form of extreme genetic engineering because it not ...
(Date:7/28/2014)...   Propeller Health , the FDA-cleared digital health ... Brad Towle as Senior Vice President, Business ... the company,s sales growth, customer acquisition and program expansion. ... his past role in the development of accountable care ... pivotal time in the industry," said David Van ...
(Date:7/28/2014)... COLLEGE STATION, Texas , July 28, 2014   ... will be a 177-key, 4-star boutique hotel in the heart of ... , Texas.  Photo - http://photos.prnewswire.com/prnh/20140725/130455 ... first hotel within ATLAS , The ... of standard rooms and suites, a sleek restaurant and bar, a ...
(Date:7/25/2014)... 25, 2014 Amgen (NASDAQ: AMGN ... a $0.61 per share dividend for the third quarter ... 5, 2014, to all stockholders of record as of ... About Amgen Amgen is committed to unlocking ... illnesses by discovering, developing, manufacturing and delivering innovative human ...
Breaking Biology Technology:Global Synthetic Biology Market 2014-2018 2Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 3Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 4Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3
... LESS Instrumentation Is Selected for Industry Leader LESS Panel ... 29 Cambridge Endo, a pioneer in the rapidly ... or SPA) market, is pleased to announce that its ... leaders selected to be on a LESS panel at ...
... Laboratory InstrumentsMENLO PARK, Calif. and NORWOOD, Mass., Jan. ... today jointly announced that Advanced Instruments Inc. has ... The two companies further announced their intention ... generation of laboratory instruments for osmolality measurement, incorporating ...
... N.J., Jan. 29 Amicus Therapeutics (Nasdaq: ... 2008 financial results after the regular close of markets ... be followed by a live conference call and webcast ... investors may access the conference call at 5 p.m. ...
Cached Biology Technology:Cleveland Clinic Selects Laparoendoscopic Single-Site Surgery (LESS) as One of the Top Ten Innovations of 2009 2Advanced Instruments Makes Strategic Investment in Cantimer, Inc. 2Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date 2
(Date:7/28/2014)... ago, MIT professor John Essigmann and colleagues from the University ... They thought if they could induce the virus to mutate ... out a strategy that our immune system uses against ... which caused HIV to mutate at an enhanced rate, as ... in a small clinical trial reported in 2011. In a ...
(Date:7/28/2014)... Eight of the top 10 U.S. cities that have ... public inconveniences as frequent road closures, overwhelmed storm drains ... a new NOAA technical report. , This nuisance flooding, ... three U.S. coasts, between 300 and 925 percent since ... Nuisance Flood Frequency Changes around the United States, also ...
(Date:7/28/2014)... MANHATTAN, Kansas He calls himself the bug hunter, ... that can only be found and identified with special ... at the Kansas State Veterinary Diagnostic Laboratory at Kansas ... his discoveries, porcine enterovirus G, which is an important ... a virus in cells, but didn,t know what it ...
Breaking Biology News(10 mins):Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 3Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3
... CORVALLIS, Ore. Researchers at Oregon State University ... the collapse of oyster seed production at a commercial ... to a level considered by the owners to be ... that elevated seawater carbon dioxide (CO2) levels, resulting in ...
... Mass. Copper the stuff of pennies and tea ... can turn carbon dioxide into hydrocarbon fuels with relatively little ... copper acts as a strong catalyst, setting off an electrochemical ... methane or methanol. Various researchers around the world have ...
... CO, USA -- April 10, 2012 -- HUNT Biosciences ... advance the clinical use of protein biomarkers, with an ... prediction of cardiovascular events such as strokes, heart attacks, ... samples and clinical data from HUNT Biosciences using SomaLogic,s ...
Cached Biology News:Ocean acidification linked to larval oyster failure 2Ocean acidification linked to larval oyster failure 3Hybrid copper-gold nanoparticles convert CO2 2Hybrid copper-gold nanoparticles convert CO2 3
Human Ig Lambda-chain, clone ICO-16, Monoclonal Antibody...
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
WNV Core Antibody...
... Rabbit polyclonal to FANCM ( Abpromise ... Antigen: Synthetic peptide derived from within ... FANCM. (Note: the amino acid sequence ... as ab27787 .) ...
Biology Products: